We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Aerie Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 153 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 156 → 0 (-156)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $703M → $0 (-$703M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 153

Holders
–
Holders Change
-156
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
153
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$73.5M
2
BlackRock
BlackRock
New York
-$53.6M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$36.9M
4
UBS Group
UBS Group
Switzerland
-$36.4M
5
WIC
Water Island Capital
New York
-$31.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
– -$6.92M -457,539 Closed
GF
27
Gabelli Funds
New York
– -$6.85M -452,567 Closed
MF
28
Magnetar Financial
Illinois
– -$6.68M -441,584 Closed
E
29
Ergoteles
New York
– -$6.48M -428,184 Closed
N
30
Nuveen
North Carolina
– -$6.11M -404,020 Closed
Charles Schwab
31
Charles Schwab
California
– -$5.38M -355,296 Closed
DCM
32
DAFNA Capital Management
California
– -$4.65M -307,232 Closed
SSA
33
Schonfeld Strategic Advisors
New York
– -$4.39M -290,416 Closed
Public Sector Pension Investment Board (PSP Investments)
34
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
– -$4.25M -281,000 Closed
EFI
35
EHP Funds Inc
Canada
– -$4.17M -275,924 Closed
EP
36
Eversept Partners
New York
– -$3.88M -256,289 Closed
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
– -$3.69M -243,976 Closed
Bank of New York Mellon
38
Bank of New York Mellon
New York
– -$3.61M -238,464 Closed
Wellington Management Group
39
Wellington Management Group
Massachusetts
– -$3.51M -231,847 Closed
GCIA
40
Gabelli & Co Investment Advisers
New York
– -$3.49M -230,400 Closed
Citadel Advisors
41
Citadel Advisors
Florida
– -$3.46M -228,542 Closed
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
– -$3.35M -221,266 Closed
Jacobs Levy Equity Management
43
Jacobs Levy Equity Management
New Jersey
– -$3.04M -200,808 Closed
Wells Fargo
44
Wells Fargo
California
– -$2.57M -169,586 Closed
CS
45
Credit Suisse
Switzerland
– -$2.49M -164,647 Closed
EWM
46
Endurance Wealth Management
Rhode Island
– -$2.42M -159,703 Closed
DA
47
DCF Advisers
Connecticut
– -$2.38M -157,665 Closed
CS
48
Candriam SCA
Luxembourg
– -$2.16M -142,745 Closed
KC
49
Kellner Capital
New York
– -$1.89M -124,575 Closed
Millennium Management
50
Millennium Management
New York
– -$1.79M -118,240 Closed
1
2
3 4 5

AERI Hedge Fund Activity: Q4 2022 in Review

0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2022, worth a combined $0 — down 100% from $703M a quarter earlier.

Sellers outnumbered buyers: 153 funds closed out of AERI and 0 opened new positions — a net loss of 153 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Deerfield Management, exiting entirely with an estimated $73.5M sold.

  • 0 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2022, down from 156 in Q3 2022.
  • Funds reported $0 of Aerie Pharmaceuticals stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Aerie Pharmaceuticals positions in Q4 2022 and 153 closed out, a net change of -153 holders.
  • The largest Aerie Pharmaceuticals seller in Q4 2022 was Deerfield Management, an estimated $73.5M sold.

Based on aggregated 13F filings for Q4 2022.